Yuan, Huijun
Chen, Shaoyi
Duncan, Matthew R.
de Rivero Vaccari, Juan Pablo
Keane, Robert W.
Dalton Dietrich, W.
Chou, Tsung-Han
Benny, Merline
Schmidt, Augusto F.
Young, Karen
Park, Kevin K.
Porciatti, Vittorio
Elizabeth Hartnett, M.
Wu, Shu
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (1R01HL156803)
Article History
Received: 12 October 2023
Accepted: 28 March 2024
First Online: 6 May 2024
Declarations
:
: JPdRV, WDD, and RWK are co-founders and managing members of InflamaCORE, LLC and have licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. JPdRV, WDD, and RWK are Scientific Advisory Board Members of ZyVersa Therapeutics. SW has a patent with a U.S. Patent Application No. 63/543,835 titled: Use of anti-ASC antibody in the treating of ocular disorders.